...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Will Hepalink make a move for RVX?

Nonsense, Board would never approve, with BTD and a favorable study in Type2 with Covid19, RVX value is 10 times what you suggest.  Annual royalites would exceed your buy out.  Take a real look, go back to the 2015 annual meeting, see last 25 minutes of 87 minute meeting.  Yes I know, some say who knows what the study will bring, than you really do not understand how Apabetalone interacts with each cell.  13 years of testing live patients, this is a very safe drug with many benefits.  The Board would reject the offer.

Share
New Message
Please login to post a reply